Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1995-06-07
1999-09-21
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4352351, 435 693, 935 65, A61K 39245
Patent
active
059550880
ABSTRACT:
The present invention relates to the field of infectious diseases and ophthalmology. More particularly, the invention relates to compositions and methods for vaccination against Herpes Simplex Virus which rely on preparations comprising a mixture of five, six, or seven HSV glycoproteins selected from the group consisting of gB, gC, gD, gE, gG, gH, and gI.
REFERENCES:
patent: 4317811 (1982-03-01), Bertland et al.
patent: 4374127 (1983-02-01), Larson et al.
patent: 4859587 (1989-08-01), Roizman
patent: 4891315 (1990-01-01), Watson et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5244792 (1993-09-01), Burke et al.
Stranberry et al, The J. of Infectious Diseases, 1987, vol. 155 (5), pp. 914-920.
Jennings et al, 1988, Arch Virol. , vol. 98, pp. 137-153.
Erturk et al, 1989, Vaccine, vol. 7, pp. 431-436.
Abbott et al., Adrenergic Induction of HSV-1 Ocular Shedding in Rabbits. J. Ocular Pharm., 2(1):41-54 (1986).
Ashley, Personal communication (1990).
Berman et al., Efficacy of Recombinant Glycoprotein D Subunit Vaccines on the Development of Primary, Recurrent, and Latent Genital Infections with Herpes Simplex Virus Type 2 in Guinea Pigs. J. Infec. Dis., 157(5):897-902 (1988).
Blacklaws et al., Immunogenicity of herpes simplex type 1 glycoproteins expressed in vaccinia virus recombinants. Virology, 177:727-736 (1990).
Borenstein et al., Immunization of rabbits with recombinant treponema palladium Surface Antigen 4D alters the course of experimental syphilis. J. Immunol., 140:2415-2421 (1988).
Centifanto-Fitzgerald et al., Herpes Simplex Virus Latency in the Rabbit Trigeminal Ganglia: Ganglionic Superinfection (42064). Proc. Soc. Experimental Biology and Medicine, 179:55-67 (1985).
Demangone et al., Effects of acyclovir therapy during simultaneous reactivation of latent HSV-1 in rabbits. Antiviral Research, 7:237-243 (1987).
Frenkel et al., A randomized double blind, placebo-controlled phase 1 trial of a herpes simplex virus purified glycoprotein (gD1) vaccine. Interscience Con. on Antimicrobial Agents & Chemo., 206 (1990).
Ghiasi et al., Baculovirus Expressed Glycoprotein E (gE) of Herpes Simplex Virus Type 1 (HSV-1) Protects Mice against Lethal Intraperitoneal and Lethal Ocular HSV-1 Challenge. Virology, 188:469-476 (1992).
Ghiasi et al., Baculovirus-Expressed Glycoprotein G of Herpes Simplex Virus Type 1 Partially Protects Vaccinated Mice against Lethal HSV-1 Challenge. Virology, 190:233-239 (1992).
Ghiasi et al., Baculovirus expressed herpes simplex type 1 glycoprotein C protects mice from lethal HSV-1 infection. Antiviral Research, 18:291-302 (1992).
Ghiasi et al., Cell surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus infected cells. Virology, 185:187-194 (1991).
Ghiasi et al., Expression of herpes simplex virus type 1 glycoprotein B in insect cells: Initial analysis of its biochemical and immunological properties. Virus Research, 22:25-39 (1991).
Ghiasi et al., Expression of Herpes Simplex Virus Type 1 Glycoprotein I in Baculovirus: Preliminary Biochemical Characterization and Protection Studies. J. Virol., 66:2505-2509 (1992).
Ghiasi et al., Expression of Seven Herpes Simplex Virus Type 1 Glycoproteins (gB, gC, gD, gG, gH, and gI): Comparative Protection against Lethal Challenge in Mice. J. Virology, 68(4):2118-2126 (1994).
Ghiasi et al., High level expression of each of the seven herpes simplex virus glycoproteins in insect cells using baculovirus expression vectors: subsequent use as vaccines. Invest. Ophthalmol. Visual Sci., vol. 32, No. 4, p. 806 (1991) Abstract 686.
Ghiasi et al., Immunoselection of recombinant baculovirus expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D. Arch. Virol., 121:163-178 (1991).
Goldstein et al., Factor(s) present in herpes simplex virus type 1 infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology, 166:41-51 (1988).
Gompels et al., The Properties and Sequence of Glycoprotein H of Herpes Simplex Virus Type 1. Virology, 153:230-247 (1986).
Green et al., Study of HSV-1 DNA species from trigeminal ganglia of rabbits during acute and latent infections. Current Eye Research, 6(1):85-89 (1987).
Harrild, Humoral response to herpes simplex virus infection. In: The Herpesviruses, edited by Roizman, B., New York, Plenum Press, pp. 69-86 (1985).
Hill et al., Lack of Efficacy of Adenosine-5'-Monophosphate Against HSV-1 Ocular Shedding in Rabbits. J. Ocular Pharm., 3(1):31-38 (1987).
Hill et al., Timolol Induces HSV-1 Ocular Shedding in the Latently Infected Rabbit. Invest. Ophthalmol. & Visual Sci., 28:585-590 (1987).
Inumaru et al., Expression of bluetongue virus group specific antigen VP3 in insect cells by a baculovirus vector: Its use for the detection of bluetongue virus antibodies. J. Gen. Virol., 68:1627-1635 (1987).
Jarvis et al., Glycosylation and secretion of human tissue plasminogen activator in recombinant baculovirus infected insect cells. Mol. Cell. Biol., 9:214-223 (1989).
Johnson et al., Identification of a Novel Herpes Simplex Virus Type 1 induced glycoprotein which complexes with gE and binds immunoglobulin. J. Virol., 61: 2208-2216 (1987).
Kern et al., Vaccine Therapy in Recurrent Herpes Simplex. Arch. Derm., 89:844-845 (1964).
Kino et al., Immunogenicity of herpes simplex virus glycoprotein gB-1-related protein produced in yeast. Vaccine, 7:155-160.
Kino et al., Immunogenicity of Purified Glycoprotein gB of Herpes Simplex Virus. Archives of Virology, 89:69-80 (1986).
Klein, Reinfections and site-specific immunity in herpes simplex virus infections. Vaccine, 7:380-381 (1989).
Krishna et al., Expression of glycoprotein D of herpes simplex virus type 1 in a Recombinant Baculovirus: Protective Responses and T Cell Recognition of the Recombinant-infected Cell Extracts. J. Gen. Virol., 70:1805-1814 (1989).
Kuroda et al., The Oligosaccharides of Influenza Virus Hemagglutinin Expressed in Insect Cells by a Baculovirus Vector. Virology, 174:418-429 (1990).
Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227:680-685 (1970).
Lee et al., Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA. J. Virol., 43:41-49 (1982).
Maeda, Expression of Foreign Genes in Insects Using Baculovirus Vectors. Ann. Rev. Entomol. 34:351-372 (1989).
Mathews et al., Synthesis and processing glycoprotein D of herpes simplex virus types 1 and 2 in an in vitro system. J. Virol., 48:521-553 (1983).
Matsuura et al., Baculovirus expression vectors: The requirements for high level expression of proteins, including glycoproteins. J. Gen. Virol., 68:1233-1250 (1987).
McGeoch et al., The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1. J. gen. Virol. 69:1531-1574 (1988).
Mishkin et al., Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models. Vaccine, 9:147-153 (1991).
Morein et al., Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature, 308:457-460 (1984).
Nesburn et al., Efficacy and safety of therapeutic systemic HSV vaccines in the rabbit ocular recurrence model. Invest. Ophthalmol. Visual Sci., vol. 32, No. 4, p. 854 (1991) Abstract 917.
Nesburn et al., Isolation of herpes simplex virus: Isolation from rabbit trigeminal ganglia between episodes of recurrent ocular infection. Arch. Ophthalmol., 88:412-417 (1972).
Nesburn et al., Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest. Ophthalmol. Vis. Sci., 31:77-82 (1990).
Nesburn, Report of the corneal disease panel: Vision Research: A national plan 1983-1987. vol. II, part III, edited by Nesburn, A.B., St. Louis, MO.
O'Brien, Herpetic Eye Diseases in Animals as Models for Therapeutic Studies of Acute and Latent Herpesvirus Infections. In: Herpesvirus, edited by Rapp, F., New York, Alan R. Liss, Inc., pp. 101-120 (1984).
Pa
Ghiasi Homayan
Nesburn Anthony B.
Wechsler Steven L.
Cedars-Sinai Medical Center
Mosher Mary E.
Salimi Ali R.
LandOfFree
Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-77672